moneyheap
NVO · Analysis updated Nov 4, 2026, 9:03 AM ET
Why is Novo Nordisk A/S (NVO) stock moving?
Novo Nordisk reported Q3 results on Nov 4 that beat expectations on an adjusted basis. Adjusted sales rose 4% at CER to DKK 79.2B and adjusted operating profit rose 27% to DKK 31.7B. Management raised 2026 guidance for the third time this year, to -2% to +2% for both sales and operating profit. It also lifted free-cash-flow guidance to DKK 60-70B. The Wegovy pill is the main driver, with Q3 sales of DKK 5.39B, well above the DKK 4.62B consensus. Weak spots remain: US injectable Wegovy sales fell, and reported operating profit dropped 9% because of DKK 8.7B of impairments. Planned US price cuts and competition from Eli Lilly are still concerns. Shares closed at $40.19 on Nov 3 after climbing from about $38.29 on Oct 28. Premarket trading pointed to a gain of roughly 3.5-5.8%, which would put the stock above the recent $40.78 high. Heavier volume ahead of earnings fits that setup. The 4.4% dividend yield and low P/E add valuation support, but analyst targets near $45 and mixed views, such as a Jefferies Hold, suggest the gains may be contested.
News behind the analysis
- Novo Nordisk Q3 profit beats forecast; raises 2026 guidanceReuters reports Q3 adjusted operating profit came in above expectations. Novo also raised its full-year profit and sales outlook.
- Why is Novo Nordisk stock surging today?The stock rose 5.8% after a Q3 beat and a guidance raise. It is the first time this year management has signalled annual sales could grow versus 2025.
- Novo Nordisk Q3 2026 slides: sales recover, outlook raised on GLP-1 growthAdjusted sales were DKK 79.2B, up 4% at CER, and adjusted operating profit rose 27%. Full-year sales and profit guidance moved to -2% to +2%, from -6% to 0%.
- Novo Nordisk Lifted Its Outlook Again, Thanks To Wegovy PillsWegovy pill sales reached DKK 5.39B and beat forecasts. US injectable Wegovy sales fell 13% at constant exchange rates.
- Novo Nordisk - Q3 2026 Earnings BriefRevenue beat consensus by 8% and adjusted operating profit beat by 12%. Free-cash-flow guidance rose to DKK 60-70B.
- Novo Nordisk Hikes 2026 Outlook AgainThis was the third outlook raise this year. The Wegovy pill beat Q3 sales forecasts as Novo tries to win back ground from Eli Lilly.
- Earnings call transcript: Novo Nordisk rises on Q3 2026 growth outlookThe stock rose about 5% premarket. Investors looked past the headline GAAP-style miss to the sales recovery and the raised guidance. More than 8M cumulative US Wegovy pill prescriptions were reported.
- Novo Nordisk Q3 Earnings Beat Boosts Confidence in Dividend SustainabilityNon-GAAP EPS and revenue beat estimates. The dividend yield is about 4.4% with a low payout ratio.
- Financial report for the period 1 January 2026 to 30 September 2026 (Form 6-K)Reported operating profit fell 9% at CER because of DKK 8.7B of non-cash impairments. These were tied to ziltivekimab and the manufacturing network.
- Novo Nordisk draws attention ahead of earnings: NVO gains momentumNVO traded near $40.46 ahead of the Nov 4 results, above its short-term moving averages.